The U.S. Food and Drug Administration (FDA) approved FluMist on September 20, 2024, marking the first influenza (flu) vaccine authorized for at-home use. This approval aims to increase accessibility and convenience for individuals seeking protection against the flu.
FluMist: A Needle-Free Option
FluMist is administered as a nasal spray and utilizes a weakened form of live influenza virus strains A and B to stimulate a lasting immune response. Initially approved in 2003 for individuals aged 5 to 49, its use was later extended to children aged 2 to 5 in 2007. Previously, administration was restricted to medical providers in clinical settings.
Expanding Access Through At-Home Administration
Under the new FDA approval, adults up to 49 years of age can self-administer FluMist. Caregivers can administer the vaccine to individuals between 2 and 17 years old. A prescription remains necessary for at-home use. Starting with the 2025-2026 flu season, individuals 18 years and older can order FluMist through a third-party online pharmacy via FluMist's website. This process involves completing an eligibility assessment, followed by pharmacist approval before the vaccine is shipped.
Impact and Availability
The FDA anticipates that this new option will enhance convenience and flexibility, leading to increased access to flu vaccination. FluMist is expected to be available for at-home use during the 2025-2026 flu season.
